IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 93.31

Change

-0.45 (-0.48)%

Market Cap

N/A

Volume

0.09M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.97 (-0.66%)

USD 40.26B
FHLC Fidelity® MSCI Health Care In..

-0.43 (-0.61%)

USD 2.86B
FXH First Trust Health Care AlphaD..

-0.16 (-0.15%)

USD 1.18B
XHE SPDR® S&P Health Care Equipme..

+1.18 (+1.33%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.06 (+0.24%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.28 (+0.73%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-0.35 (-0.37%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.35 (+1.23%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.26 (-0.40%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.45 (+1.56%)

USD 0.01B

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

+0.67 (+0.48%)

USD 1.43B
XHC:CA iShares Global Healthcare.. 99.90 % 0.65 %

-0.49 (0.48%)

CAD 0.63B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -46.20% 38% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.20% 38% F 12% F
Trailing 12 Months  
Capital Gain -42.84% 29% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.84% 29% F 11% F
Trailing 5 Years  
Capital Gain -26.99% 43% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.99% 43% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 6.37% 62% D 58% F
Dividend Return 7.32% 62% D 54% F
Total Return 0.95% 74% C 22% F
Risk Return Profile  
Volatility (Standard Deviation) 12.59% 81% B- 71% C-
Risk Adjusted Return 58.13% 86% B+ 75% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike